Real-world Comparative Effectiveness of Evolocumab Versus Ezetimibe in Reducing the Risk of Fatal and Nonfatal Myocardial Infarction (20240027)

Study identification

• EU PAS number:
  EUPAS1000000522
• Study ID:
  1000000522
• Official title and acronym:
  Real-world Comparative Effectiveness of Evolocumab Versus Ezetimibe in Reducing the Risk of Fatal and Nonfatal Myocardial Infarction (20240027)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  This study is to compare treatment effectiveness of evolocumab vs. ezetimibe in reducing risk of fatal and nonfatal myocardial infarction among patients with atherosclerotic cardiovascular disease. ; It is a retrospective secondary database analysis using a large, US claims dataset.
• Study status:
  Ongoing

Research institutions and networks

Institutions

It is an Amgen sponsored study in collaboration with Target RWE

Study timelines

Date when funding contract was signed

Planned: 28/02/2024

Actual: 28/02/2024

Study start date

Planned: 01/04/2025

Actual: 01/04/2025

Data analysis start date

Planned: 15/04/2025

Actual: 15/04/2025

Date of final study report

Planned: 31/03/2026

Sources of funding

More details on funding

Amgen Inc.

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable